The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Tumor Markers in Neuroendocrine Tumors
Abstract
Most neuroendocrine tumors produce and secrete a multitude of peptide hormones and amines. Some of these substances cause a specific clinical syndrome: carcinoid, Zollinger-Ellison, hyperglycemic, glucagonoma and WDHA syndrome. Specific markers for these syndromes are basal and/or stimulated levels of urinary 5-HIAA, serum or plasma gastrin, insulin, glucagon and vasoactive intestinal polypeptide, respectively. Some carcinoid tumors and about one third of endocrine pancreatic tumors do not present any clinical symptoms and are called ‘nonfunctioning’ tumors. Therefore, general tumor markers such as chromogranin A, pancreatic polypeptide, serum neuron-specific enolase and subunits of glycoprotein hormones have been used for screening purposes in patients without distinct clinical hormone-related symptoms. Among these general tumor markers chromogranin A, although its precise function is not yet established, has been shown to be a very sensitive and specific serum marker for various types of neuroendocrine tumors. This is because it may also be elevated in many cases of less well-differentiated tumors of neuroendocrine origin that do not secrete known hormones. At the moment, chromogranin A is considered the best general neuroendocrine serum or plasma marker available both for diagnosis and therapeutic evaluation and is increased in 50–100% of patients with various neuroendocrine tumors. Chromogranin A serum or plasma levels reflect tumor load, and it may be an independent marker of prognosis in patients with midgut carcinoids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion
Tatemoto, K., Efendić, S., Mutt, V., Makk, G., Feistner, G. J., & Barchas, J. D. (1986) · Nature · doi:10.1038/324476a0 · Cited by 681
The chromogranins A and B: The first 25 years and future perspectives
Winkler, H., & Fischer-Colbrie, R. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90222-n · Cited by 655
BLASCHKO, H., COMLINE, R. S., SCHNEIDER, F. H., SILVER, M., & SMITH, A. D. (1967) · Nature · doi:10.1038/215058a0 · Cited by 520
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008215730767 · Cited by 455
Self-citationHelena Michelson, C. B. (2000) · Acta Oncologica · doi:10.1080/028418600750013384 · Cited by 379
Wiedenmann, B., & Huttner, W. B. (1989) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890062 · Cited by 322
Bajetta, E., Ferrari, L., Martinetti, A., Celio, L., Procopio, G., Artale, S., Zilembo, N., Di Bartolomeo, M., Seregni, E., & Bombardieri, E. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990901)86:5<858::aid-cncr23>3.0.co;2-8 · Cited by 289
Stridsberg, M., Öberg, K., Li, Q., Engström, U., & Lundqvist, G. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1440049 · Cited by 278
Self-citationNORHEIM, I., ÖBERG, K., THEODORSSON-NORHEIM, E., LINDGREN, P. G., LUNDQVIST, G., MAGNUSSON, A., WIDE, L., & WILANDER, E. (1987) · Annals of Surgery · doi:10.1097/00000658-198708000-00001 · Cited by 271
Self-citationChromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker*
DEFTOS, L. J. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-2-181 · Cited by 261
Cited by
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Multifunctional α-enolase: its role in diseases
Pancholi, V. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000910 · Cited by 838
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Metadata
- Authors
- Eriksson, B., Öberg, K., & Stridsberg, M.
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2000
- Volume
- 62
- Issue
- Suppl. 1
- Pages
- 33-38
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- OpenAlex
- W2025301846
- Cited by
- 299
- References
- 42
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Markers in Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1159/000051853
- The paper
- Eriksson, B., Öberg, K., & Stridsberg, M. (2000). Tumor Markers in Neuroendocrine Tumors. Digestion. https://doi.org/10.1159/000051853
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.